Electronic Theses and Dissertation

Latar belakang: osteoartritis (oa) lutut merupakan penyakit degeneratif sendi yang ditandai dengan kerusakan rawan sendi akibat proses inflamasi kronis. terapi konvensional seperti nsaid dan kortikosteroid hanya menekan gejala, namun tidak menghambat progresivitas penyakit. kolkisin dengan efek antiinflamasi dan antifibrotik berpotensi memperbaiki struktur dan fungsi sendi. ctx-ii adalah biomarker degradasi kolagen tipe ii yang merupakan komponen tulang rawan pada sendi. skala womac adalah penilaian kualitas hidup pada pasien oa yang meliputi nyeri, kekakuan, dan fungsi fisik. tujuan: menilai perbedaan kadar c-terminal telopeptide of type-ii collagen dan western ontario mcmaster universities osteoarthritis index pasien osteoartritis lutut pre dan post terapi kolkisin. metode: penelitian ini merupakan studi pre–post eksperimental yang melibatkan 40 pasien oa lutut yang menerima terapi kolkisin 2×0,5 mg selama 4 minggu. variabel utama adalah kadar ctx-ii dan skala womac. analisis statistik menggunakan uji paired t-test dan wilcoxon signed rank test dengan tingkat signifikansi p

Background: Knee osteoarthritis (OA) is a degenerative joint disease characterized by joint cartilage damage due to chronic inflammation. Conventional therapies such as NSAIDs and corticosteroids only suppress symptoms, but do not inhibit disease progression. Colchicine, with its anti-inflammatory and antifibrotic effects, has the potential to improve joint structure and function. CTX-II is a biomarker of type II collagen degradation, which is a component of joint cartilage. The WOMAC scale is a quality of life assessment for OA patients that includes pain, stiffness, and physical function. Objective: assessing Differences In C-Terminal Telopeptide Of Type-II Collagen Levels (CTX-II) and Western Ontario Mcmaster Universities Osteoarthritis Index Scores (WOMAC) in patients knee osteoarthritis pre and post colchicine treatment Method: This study was a pre–post experimental study involving 40 patients with knee OA who received colchicine therapy at a dose of 2×0.5 mg for 4 weeks. The main variables were CTX-II levels and WOMAC scores. Statistical analysis used paired t-tests and Wilcoxon signed rank tests with a significance level of p